CCDC126

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, CCDC126 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CCDC126 data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CCDC126 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC126 expression acts as an unfavorable survival marker.

OV, LUAD, and CESC are the cancer types where CCDC126 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
OVOSMedianII,III,IV0.1800.844<.00136view →
LUADOSMedianAll0.0680.788<.00124view →
CESCOSMedianII,III,IV0.0470.830<.00112view →
UCECOSMedianIV0.1330.754<.00112view →
Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CCDC126–OV (OS)

Kaplan–Meier survival curve for CCDC126 mutant vs wild-type samples in OV.

Open the OV breakdown →

Exploration